Fund Holdings — Enavate Sciences GP, LLC

Total Portfolio Value:
$279.76M
Total Bought:
$74.23M
Total Sold:
$22.76M
Net Transaction:
+$51.47M
Securities
▲▼
SharesValue
Q2 2026
▲▼
Q3 2026
▲▼
Change
▲▼
Q2 2026
▲▼
Q3 2026
▲▼
Weight (%)
▲▼
Change
▲▼
Zenas BioPharma, Inc.(ZBIO)3,919,1592,919,159-1,000,000$99.47M$78.73M28.14%-$20.74M
Immunome, Inc.(IMNM)3,613,7993,613,7990$76.58M$77.73M27.79%+$1.16M
Braveheart Bio Inc03,674,656+3,674,656$0$74.23M26.53%+$74.23M
Sionna Therapeutics Inc2,478,0302,478,0300$109.01M$13.03M4.66%-$95.97M
Upstream Bio Inc2,459,7032,459,7030$17.02M$12.96M4.63%-$4.06M
Bridgebio Oncology Therapeut2,626,9462,626,9460$20.02M$10.77M3.85%-$9.25M
Compass Therapeutics Inc7,788,1507,788,1500$17.06M$8.10M2.90%-$8.96M
Camp4 Therapeutics Corp1,425,5411,041,127-384,414$6.23M$4.21M1.50%-$2.02M
Page 1 of 1
Enavate Sciences GP, LLC — 13F Holdings — Q3 2026 | TickerTrail